Document is current
Any future updates will be listed below
-
Authors
Donnelly, John P.
Dai, Yuling
Colantonio, Lisandro D.
Zhao, Hong
Safford, Monika M.
Baddley, John W.
Muntner, Paul
Wang, Henry E.
-
Funding
Funding for this research was provided by:
NINR (R01-NR012726)
NCRR (UL1-RR025777)
NINDS (U01-NS041588)
NIGMS (F31-GM122180)
NHLBI (K12-HL138039)
- License Information
-
More Information
Article History
Received: 24 May 2019
Accepted: 24 February 2020
First Online: 4 March 2020
Ethics approval and consent to participate
: Consistent with the REGARDS study protocol approved by the University of Alabama at Birmingham Institutional Review Board and the institutional review boards governing human subjects research at participating institutions, participants provided verbal consent before completing the baseline telephone interview and written informed consent before completing the in-home examination. The consent form included permission to merge participant data with Medicare claims. For this analysis, we conducted an observational study using data from REGARDS. The study was approved by the University of Alabama at Birmingham Institutional Review Board with waiver of the requirement for additional informed consent (approval number X090531004). Additional information related to ethics approval, including example consent forms, is available at the REGARDS study website ().
: Not Applicable.
: Dr. Baddley reports consulting for Merck and Pfizer. Drs. Safford and Muntner report investigator-initiated research grants from Amgen Inc. All others have no disclosures.
